Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) have been given an average rating of “Hold” by the seven brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $24.00.
A number of brokerages have issued reports on SLN. William Blair cut shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, October 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, October 15th. Chardan Capital downgraded Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Morgan Stanley lifted their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Finally, HC Wainwright cut Silence Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $75.00 to $20.00 in a report on Wednesday, October 21st.
Read Our Latest Stock Report on Silence Therapeutics
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in SLN. Soleus Capital Management L.P. raised its stake in shares of Silence Therapeutics by 278.7% during the 3rd quarter. Soleus Capital Management L.P. now owns 2,385,700 shares of the company’s stock worth $26,076,000 after buying an additional 1,755,700 shares during the last quarter. Toronto Dominion Bank purchased a new stake in shares of Silence Therapeutics in the 3rd quarter worth about $5,314,000. 5AM Venture Management LLC purchased a new stake in shares of Silence Therapeutics in the 2nd quarter worth about $5,228,676. Goldman Sachs Group Inc. grew its stake in Silence Therapeutics by 196.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 462,831 shares of the company’s stock valued at $5,059,000 after acquiring an additional 306,902 shares during the last quarter. Finally, Aberdeen Group plc acquired a new stake in Silence Therapeutics in the 3rd quarter valued at about $2,207,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.
Silence Therapeutics Price Performance
NASDAQ:SLN opened at $19.81 on Friday. The firm’s fifty day simple moving average is $15.28 and its 200-day simple moving average is $10.13. The stock has a market cap of $1.23 billion, a PE ratio of -18.51 and a beta of 1.34. Silence Therapeutics has a fifty-two week low of $4.19 and a fifty-two week high of $19.86.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.13). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 56.32%. Equities analysts anticipate that Silence Therapeutics will post -0.81 earnings per share for the current year.
Silence Therapeutics Company Profile
Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
